Effect of a Mobile App for the Pharmacotherapeutic Follow-Up of Patients With Cancer on Their Health Outcomes: Quasi-Experimental Study.
app
e-OncoSalud
oncology
oral antineoplastic agent
smartphone
Journal
JMIR mHealth and uHealth
ISSN: 2291-5222
Titre abrégé: JMIR Mhealth Uhealth
Pays: Canada
ID NLM: 101624439
Informations de publication
Date de publication:
16 10 2020
16 10 2020
Historique:
received:
20
05
2020
accepted:
13
09
2020
revised:
23
08
2020
entrez:
16
10
2020
pubmed:
17
10
2020
medline:
28
4
2021
Statut:
epublish
Résumé
Oral antineoplastic agents (OAAs) have revolutionized cancer management. However, they have been reported with adverse side effects and drug-drug interactions. Moreover, patient adherence to OAA treatment is critical. Mobile apps can enable remote and real-time pharmacotherapeutic monitoring of patients, while also promoting patient autonomy in their health care. The primary objective was to analyze the effect of using a mobile app for the follow-up of patients with oncohematological malignancies undergoing treatment with OAAs on their health outcomes. The secondary objectives were to analyze the role of the app in communication with health care professionals and patient satisfaction with the app. We performed a comparative, quasi-experimental study based on a prepost intervention with 101 patients (control group, n=51, traditional pharmacotherapeutic follow-up vs intervention group, n=50, follow-up through e-OncoSalud, a custom-designed app that promotes follow-up at home and the safety of patients receiving OAAs). The effect of this app on drug safety, adherence to treatment, and quality of life was evaluated. With regard to drug safety, 73% (37/51) of the patients in the control group and 70% (35/50) of the patients in the intervention group (P=.01) presented with drug-related problems. The probability of detecting an insufficiently treated health problem in the intervention group was significantly higher than that in the control group (P=.04). The proportion of patients who presented with side effects in the intervention group was significantly lower than that in the control group (P>.99). In the control group, 49% (25/51) of the patients consumed some health resources during the first 6 months of treatment compared with 36% (18/50) of the patients in the intervention group (P=.76). Adherence to treatment was 97.6% (SD 7.9) in the intervention group, which was significantly higher than that in the control group (92.9% [SD 10.0]; P=.02). The EuroQol-5D in the intervention group yielded a mean (SD) index of 0.875 (0.156), which was significantly higher than that in the control group (0.741 [0.177]; P<.001). Approximately 60% (29/50) of the patients used the messaging module to communicate with pharmacists. The most frequent types of messages were acknowledgments (77/283, 27.2%), doubts about contraindications and interactions with OAAs (70/283, 24.7%), and consultations for adverse reactions to treatment (39/283, 13.8%). The satisfaction with the app survey conducted in the intervention group yielded an overall mean (SD) score of 9.1 (0.4) out of 10. Use of e-OncoSalud for the real-time follow-up of patients receiving OAAs facilitated the optimization of some health outcomes. The intervention group had significantly higher health-related quality of life and adherence to treatment than the control group. Further, the probability of the intervention group presenting with side effects was significantly lower than that of the control group.
Sections du résumé
BACKGROUND
Oral antineoplastic agents (OAAs) have revolutionized cancer management. However, they have been reported with adverse side effects and drug-drug interactions. Moreover, patient adherence to OAA treatment is critical. Mobile apps can enable remote and real-time pharmacotherapeutic monitoring of patients, while also promoting patient autonomy in their health care.
OBJECTIVE
The primary objective was to analyze the effect of using a mobile app for the follow-up of patients with oncohematological malignancies undergoing treatment with OAAs on their health outcomes. The secondary objectives were to analyze the role of the app in communication with health care professionals and patient satisfaction with the app.
METHODS
We performed a comparative, quasi-experimental study based on a prepost intervention with 101 patients (control group, n=51, traditional pharmacotherapeutic follow-up vs intervention group, n=50, follow-up through e-OncoSalud, a custom-designed app that promotes follow-up at home and the safety of patients receiving OAAs). The effect of this app on drug safety, adherence to treatment, and quality of life was evaluated.
RESULTS
With regard to drug safety, 73% (37/51) of the patients in the control group and 70% (35/50) of the patients in the intervention group (P=.01) presented with drug-related problems. The probability of detecting an insufficiently treated health problem in the intervention group was significantly higher than that in the control group (P=.04). The proportion of patients who presented with side effects in the intervention group was significantly lower than that in the control group (P>.99). In the control group, 49% (25/51) of the patients consumed some health resources during the first 6 months of treatment compared with 36% (18/50) of the patients in the intervention group (P=.76). Adherence to treatment was 97.6% (SD 7.9) in the intervention group, which was significantly higher than that in the control group (92.9% [SD 10.0]; P=.02). The EuroQol-5D in the intervention group yielded a mean (SD) index of 0.875 (0.156), which was significantly higher than that in the control group (0.741 [0.177]; P<.001). Approximately 60% (29/50) of the patients used the messaging module to communicate with pharmacists. The most frequent types of messages were acknowledgments (77/283, 27.2%), doubts about contraindications and interactions with OAAs (70/283, 24.7%), and consultations for adverse reactions to treatment (39/283, 13.8%). The satisfaction with the app survey conducted in the intervention group yielded an overall mean (SD) score of 9.1 (0.4) out of 10.
CONCLUSIONS
Use of e-OncoSalud for the real-time follow-up of patients receiving OAAs facilitated the optimization of some health outcomes. The intervention group had significantly higher health-related quality of life and adherence to treatment than the control group. Further, the probability of the intervention group presenting with side effects was significantly lower than that of the control group.
Identifiants
pubmed: 33064100
pii: v8i10e20480
doi: 10.2196/20480
pmc: PMC7600015
doi:
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
e20480Informations de copyright
©Roberto Collado-Borrell, Vicente Escudero-Vilaplana, Almudena Ribed, Cristina Gonzalez-Anleo, Maite Martin-Conde, Rosa Romero-Jimenez, Irene Iglesias-Peinado, Ana Herranz-Alonso, Maria Sanjurjo-Saez. Originally published in JMIR mHealth and uHealth (http://mhealth.jmir.org), 16.10.2020.
Références
JMIR Mhealth Uhealth. 2017 Dec 04;5(12):e187
pubmed: 29203459
J Med Internet Res. 2018 Oct 29;20(10):e273
pubmed: 30578205
J Med Internet Res. 2013 Dec 23;15(12):e287
pubmed: 24366061
Farm Hosp. 2016 Jan 01;40(1):25-35
pubmed: 26882831
J Community Support Oncol. 2015 May;13(5):188-94
pubmed: 27119127
J Med Internet Res. 2019 Jan 24;21(1):e10875
pubmed: 30679145
JAMA Netw Open. 2018 Sep 7;1(5):e181617
pubmed: 30646139
Appl Clin Inform. 2018 Oct;9(4):833-840
pubmed: 30463094
J Oncol Pharm Pract. 2020 Jan;26(1):105-115
pubmed: 30955468
J Natl Cancer Inst. 2017 Sep 1;109(9):
pubmed: 28423407
Eur J Cancer Care (Engl). 2017 May;26(3):
pubmed: 26872286
J Cancer Res Clin Oncol. 2016 Nov;142(11):2319-30
pubmed: 27316629
Med Sci Monit. 2018 Sep 04;24:6151-6156
pubmed: 30178780
J Clin Oncol. 2009 Feb 20;27(6):891-6
pubmed: 19114695
J Am Pharm Assoc (2003). 2013 Mar-Apr;53(2):172-81
pubmed: 23571625
Stud Health Technol Inform. 2009;146:149-53
pubmed: 19592825
J Med Internet Res. 2018 Oct 23;20(10):e11006
pubmed: 30355554
Int J Clin Pharm. 2016 Apr;38(2):280-8
pubmed: 26715547
AMIA Annu Symp Proc. 2007 Oct 11;:635-9
pubmed: 18693913
J Clin Oncol. 2010 May 10;28(14):2381-8
pubmed: 20385986